Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHY Oral Gel is an over-the-counter desensitizing oral gel developed by Group Pharmaceuticals, specifically formulated to manage dentinal hypersensitivity (sensitive teeth). The product contains a combination of potassium nitrate and sodium monofluorophosphate. Potassium nitrate acts as a nerve desensitizer by increasing the extracellular concentration of potassium ions around the dental nerve fibers; this leads to a sustained depolarization of the nerve membrane, effectively blocking the transmission of pain stimuli to the brain. Sodium monofluorophosphate serves as a fluoride source that promotes the remineralization of tooth enamel and helps occlude (plug) exposed dentinal tubules. This dual action provides relief from sensitivity triggered by thermal, chemical, or mechanical stimuli while also offering protection against dental caries.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SHY Oral Gel.